---
schema_version: "secwatch.filing_event.v1"
accession: "0000105770-23-000064"
form_type: "8-K"
ticker: "WST"
cik: "0000105770"
company_name: "WEST PHARMACEUTICAL SERVICES INC"
filed_at: "2023-10-26T23:59:59+00:00"
generated_at: "2026-06-09T07:45:47.288439+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# West Pharma Q3: adj EPS $2.16, rev $747.4M; raises FY adj EPS outlook to $7.95-8.00

## Summary
- Q3 net sales $747.4M, +8.8% YoY; organic growth 5.7%.
- Reported diluted EPS $2.14 (+34.6%); adjusted diluted EPS $2.16 (+6.4%).
- FY2023 net sales guidance cut to $2.950-2.960B (from $2.970-2.995B); organic growth now 2-3%.
- FY2023 adjusted EPS guidance raised to $7.95-8.00 (from $7.65-7.80); dividend increased to $0.20/share (+5.3%).
- Proprietary Products net sales +6.3% (organic +3.2%); Contract-Mfg +20.8% (organic +17.4%).

## SEC filing metadata
- accession: 0000105770-23-000064
- form_type: 8-K
- ticker: WST
- cik: 0000105770
- company_name: WEST PHARMACEUTICAL SERVICES INC
- filed_at: 2023-10-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/0000105770-23-000064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/wst-20231026.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000105770-23-000064
- JSON: https://secwatch.observer/filing/0000105770-23-000064.json
- Plain text: https://secwatch.observer/filing/0000105770-23-000064.txt

## Key facts
- Earnings Releases
  WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2023 results: revenue Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%., EPS Reported-diluted EPS of $2.14 increased 34.6%..
  - Period: Third-Quarter 2023
  - Revenue: Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%.
  - EPS: Reported-diluted EPS of $2.14 increased 34.6%.
  - Result: reported results
  source text: West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 26, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2023, updated full-year 2023 financial guidance and declared a fourth-quarter 2023 dividend. Third-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%. • Reported-diluted EPS of $2.14 increased 34.6%.
  evidence_url: https://www.sec.gov/Archives/edgar/data/105770/000010577023000064/0000105770-23-000064-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.